Reichenbach, Patrick
Giordano Attianese, Greta Maria Paola
Ouchen, Khaoula
Cribioli, Elisabetta
Triboulet, Melanie
Ash, Sarah
Saillard, Margaux http://orcid.org/0000-0001-9467-1830
Vuillefroy de Silly, Romain http://orcid.org/0000-0001-6573-9752
Coukos, George http://orcid.org/0000-0001-8813-7367
Irving, Melita http://orcid.org/0000-0002-6849-7194
Article History
Received: 15 March 2022
Accepted: 20 February 2023
First Online: 17 April 2023
Competing interests
: In the past 3 years, G.C. has received grants and research support or has been co-investigator in clinical trials by Bristol-Myers Squibb, Tigen Pharma, Iovance, F. Hoffmann La Roche AG and Boehringer Ingelheim. The Lausanne University Hospital (CHUV) has received honoraria for advisory services that G.C. has provided to Genentech, AstraZeneca AG and EVIR. G.C. has previously received royalties from the University of Pennsylvania for CAR-T-cell therapy licensed to Novartis and Tmunity Therapeutics. A provisional patent regarding the dual inverted vector and associated methodologies for increasing virus titres as described in this manuscript has been filed (2022 U.S. Provisional Patent Application No. 63/290,528 ANTISENSE TRANSFER VECTORS AND METHODS OF USE THEREOF) with M.I., G.C., P.R. and G.M.P.G.A. as co-inventors. The other authors declare no competing interests.